News

Eli Lilly’s Mounjaro Shows Cardiovascular Benefits in Head-to-Head Trial
Eli Lilly and Company (NYSE:LLY) is one of the most profitable growth stocks to buy according to billionaires. On August 1, ...
Goldman Sachs Maintained a Buy Rating on Eli Lilly (LLY), Kept the PT Unchanged
Eli Lilly and Company (NYSE:LLY) is one of the Best Stocks to Invest in for High Returns. On July 31, Asad Haider of Goldman Sachs maintained a Buy rating on Eli Lilly and Company (NYSE:LLY) with a ...
Barchart on MSN8h
This Blue-Chip Stock Is Cooking Up a Major Growth Catalyst
Eli Lilly and Company (LLY), one of the world’s leading pharmaceutical giants, might have just unveiled its next major growth ...
Daily Journal2d
More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects
At least 26 patients have filed lawsuits in Marion County against Eli Lilly and Co. over its marketing of GLP-1 drugs ...
Medical Dialogues3d
Much Awaited Cardiac Safety Data of Tirzepatide Released
Topline results from the SURPASS-CVOT trial reveal that once-weekly tirzepatide (Mounjaro) has a cardiovascular risk profile ...